WO2014149867A1 - Cosmetic compositions and methods for inhibiting melanin synthesis - Google Patents
Cosmetic compositions and methods for inhibiting melanin synthesis Download PDFInfo
- Publication number
- WO2014149867A1 WO2014149867A1 PCT/US2014/021271 US2014021271W WO2014149867A1 WO 2014149867 A1 WO2014149867 A1 WO 2014149867A1 US 2014021271 W US2014021271 W US 2014021271W WO 2014149867 A1 WO2014149867 A1 WO 2014149867A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cosmetic composition
- skin
- weight
- cosmetic
- bisabolol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
- A61K8/062—Oil-in-water emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
- A61K8/064—Water-in-oil emulsions, e.g. Water-in-silicone emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/342—Alcohols having more than seven atoms in an unbroken chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9706—Algae
- A61K8/9711—Phaeophycota or Phaeophyta [brown algae], e.g. Fucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Definitions
- the present disclosure generally relates to cosmetic compositions including bisabolol, hexyldecanol, and undecylenoyl phenylalanine; and methods relating thereto.
- consumers often desire skin lightening products that are affordable, safe, stable, and can produce consumer-noticeable skin lightening after routine use.
- consumers may desire skin lightening products to either lighten the color of their skin and/or minimize skin spots or blotchiness.
- consumers may desire skin lightening agents to counteract fluctuations in skin color brought about by hormonal fluctuations or environmental stressors like UV light.
- At least some skin lightening agents work by targeting or influencing one or more of the steps involved in the development of skin color.
- Human skin color is attributed in part to the outermost layer of skin (i.e. epidermis) where many melanocytes may be located.
- the synthesis of melanin, pigments that may be dark brown/black or light red- yellow, is a complex process that involves the enzyme, tyrosinase, and can take place within the melanosomes of the melanocytes. These melanosomes may be transferred from the melanocyte to the keratinocytes.
- the cosmetic composition may comprise N-undecylenoyl-L-phenylalanine; from about 0.01% to about 8%, by weight of the cosmetic composition, of hexyldecanol; and from about 0.003% to about 2%, by weight of the cosmetic composition, of bisabolol.
- a method for reducing the melanin synthesis may comprise identifying a target portion of keratinous tissue in need of melanin reduction; and topically applying to the target portion of the keratinous tissue an effective amount of a cosmetic composition comprising: N-undecylenoyl-L-phenylalanine; from about 0.01% to about 8%, by weight of the cosmetic composition, of hexyldecanol; and from about 0.003% to about 2%, by weight of the cosmetic composition, of bisabolol.
- Cosmetic composition means compositions suitable for topical application on keratinous tissue.
- Derivatives include, but are not limited to, amide, ether, ester, amino, carboxyl, acetyl, and/or alcohol derivatives of a given chemical.
- Effective amount means an amount sufficient to induce one or more biological effects.
- biological effects include a change in skin color and/or a change in the synthesis of melanin (either in vitro or in vivo) such as a decrease in melanin synthesis.
- Extract as used herein, means material that may be obtained by the following procedure: Place the indicated portion of dried plant material (stem, bark, leaves, etc.) in a conical glass percolator. Add the indicated percentage of extraction solvent in a w/w ratio of 1 part plant material to 2 parts extraction solvent. When the indicated percentage of extraction solvent is less than 100%, the remaining solvent is water (e.g., 95% ethanol with 5% water, 50% ethanol with 50% water, etc.). Allow the extraction to proceed for about 16 to about 24 hours. Collect the percolate, and repeat the above process until the resulting percolate is substantially free from plant additional extract. Combine the percolates, evaporate to dryness under reduced pressure, and store the resulting extract under nitrogen at less than 4 degrees Celsius.
- Pigmentation refers to an area of skin wherein the pigmentation is greater than that of an adjacent area of skin (e.g., a pigment spot, an age spot, and the like).
- Improve skin condition or “improving skin condition” means effecting a visually and/or tactilely perceptible positive change, or benefit, in skin appearance and feel.
- Benefits include, but are not limited to, one or more of the following: reducing the appearance of wrinkles, coarse deep lines, fine lines, crevices, bumps, and large pores; thickening of keratinous tissue (e.g., building the epidermis and/or dermis and/or sub-dermal layers of the skin, and where applicable, the keratinous layers of the nail and hair shaft, to reduce skin, hair, or nail atrophy); increasing the convolution of the dermal-epidermal border (also known as the rete ridges); skin lightening; preventing loss of skin or hair elasticity, for example, due to loss, damage and/or inactivation of functional skin elastin, resulting in such conditions as elastosis, sagging, loss of skin or hair recoil from deformation; reduction in cellulite; change in
- Keratinous tissue refers to the keratin-containing layers disposed as the outermost protective covering of mammals which include, but are not limited to, skin, hair, nails, and cuticles.
- “Sallowness” as used herein means the pale color, yellow color or the like condition of skin that occurs as a result of a loss of, damage to, alterations to, and/or abnormalities in skin components such that they become colored (e.g., yellow in color) due to processes such as protein glycation and accumulation of lipofuscin or in the decrease in peripheral blood flow that typically accompanies skin aging.
- Salts as used herein, but are not limited to, sodium, potassium, calcium, ammonium, manganese, copper, and/or magnesium salts of a given chemical.
- “Signs of skin aging” as used herein, include but are not limited to, all outward visibly and tactilely perceptible manifestations, as well as any macro- or micro-effects, due to keratinous tissue aging. These signs may result from processes which include, but are not limited to, the development of textural discontinuities such as wrinkles and coarse deep wrinkles, fine lines, skin lines, crevices, bumps, large pores, unevenness or roughness; loss of skin elasticity; discoloration (including undereye circles); blotchiness; sallowness; hyperpigmented skin regions such as age spots and freckles; keratoses; abnormal differentiation; hyperkeratinization; elastosis; collagen breakdown, and other histological changes in the stratum corneum, dermis, epidermis, vascular system (e.g., telangiectasia or spider vessels), and underlying tissues (e.g., fat and/or muscle), especially those proximate to the skin.
- textural discontinuities such as
- Skin care actives means chemicals that when applied to the skin, provide a benefit or improvement to the skin. It is to be understood that skin care actives are useful not only for application to skin, but also to hair, nails and other keratinous tissue. Surprisingly, it has been discovered that a combination of bisabolol, undecylenoyl phenylalanine, and hexyldecanol may act synergistically to inhibit melanin synthesis. Without being limited to theory, it is believed that this inhibition of melanin synthesis may lead to reduced melanin levels in the upper layers of the epidermis.
- the synergistic combination of bisabolol, undecylenoyl phenylalanine, and hexyldecanol may include other known skin care actives such as niacinamide and still provide a synergistic effect.
- Cosmetic compositions including bisabolol, undecylenoyl phenylalanine, and hexyldecanol may be used, for example, to treat skin color irregularities (e.g. hyperpigmentation), lighten the color of the skin, ameliorate the signs of aging, and/or improve skin condition.
- Sample 1 included 0.1% bisabolol (shown as “Bis”).
- Sample 2 included 0.1% bisabolol, 0.00056% hexyldecanol (shown as “HD”), and 0.00056% niacinamide (shown as “Nia”).
- Sample 3 included 0.1% bisabolol, 0.00011% undecylenoyl phenylalanine (shown as "UP”), and 0.00056% niacinamide.
- Sample 4 included 0.00056% hexyldecanol, 0.00011% undecylenoyl phenylalanine, and 0.00056% niacinamide.
- Sample 5 included 0.1% bisabolol, 0.00056% hexyldecanol, and 0.00011% undecylenoyl phenylalanine.
- Sample 6 included 0.1% bisabolol, 0.00056% hexyldecanol, 0.00011% undecylenoyl phenylalanine, and 0.00056% niacinamide.
- the cosmetic compositions may be applied to mammalian keratinous tissue, in particular to human skin.
- the cosmetic compositions may take various forms.
- some non- limiting examples of forms include solutions, suspensions, lotions, creams, gels, toners, sticks, pencils, sprays, aerosols, ointments, cleansing liquid washes and solid bars, shampoos and hair conditioners, pastes, foams, powders, mousses, shaving creams, wipes, strips, patches, electrically-powered patches, wound dressing and adhesive bandages, hydrogels, film-forming products, facial and skin masks, cosmetics (e.g. foundations, eye liners, eye shadows), and the like.
- cosmetics e.g. foundations, eye liners, eye shadows
- Cosmetic compositions may include bisabolol.
- Bisabolol has previously been used as a fragrance ingredient in consumer products like fine fragrances, shampoos, soaps, and cosmetics.
- Bisabolol has also been implicated with possessing anti-inflammatory properties and has previously been included in compositions as an anti-inflammatory active.
- Bisabolol may be naturally- or synthetically-derived, or may include a mixture of natural and synthetic origin. Bisabolol may be added to the cosmetic composition, for example, in pure form, as a salt, as an extract, or in any other form. Bisabolol includes, for example, "alpha- bisabolol,” which includes (+)-alpha-bisabolol, (-)-alpha-bisabolol, (+)-epi-alpha-bisablol, (-)- epi-alpha-bisablol, and combinations thereof.
- the cosmetic compositions may include at least 0.003% of bisabolol, by weight of the cosmetic composition.
- the cosmetic compositions may include from about 0.003% to about 1%, from about 0.1% to about 1%, from about 0.003% to about 2%, from about 0.1% to about 2%, or from 0.003% to 5% of bisabolol, by weight of the cosmetic composition.
- Bisabolol may possess the following formula:
- Cosmetic compositions may also include N-undecylenoyl-L-phenylalanine (i.e. undecylenoyl phenylalanine).
- N-undecylenoyl-L-phenylalanine may be commercially available from SEPPIC and sold under the name of Sepiwhite ® .
- N-undecylenoyl-L-phenylalanine is a material that belongs to a broad class of N-acyl phenylalanine derivatives and is known as a topical skin tone evening agent.
- the cosmetic compositions may include at least about 0.0001% or more of N-undecylenoyl-L-phenylalanine, by weight of the cosmetic composition.
- the cosmetic compositions may include from about 0.0001% to about 1%, from about 0.0001% to about 2%, from about 0.0001% to about 5%, or from about 0.01% to about 2% of N- undecylenoyl-L-phenylalanine, by weight of the cosmetic composition.
- N-undecylenoyl-L-phenylalanine may possess the following formula:
- the cosmetic compositions may also include 2-hexyl-l-decanol (i.e. "hexyldecanol").
- the cosmetic compositions described herein may have a concentration of hexyldecanol greater than 0.0005%, 0.1%, 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 8%, 10% or 12% and/or less than 20%, 18%, 16%, 15% or 14% by weight of the cosmetic composition.
- the cosmetic compositions described herein may have a concentration of hexyldecanol of from about 0.05% to about 8%, from about 0.01% to about 5%, or from about 0.01% to about 8%, by weight of the cosmetic composition.
- Hexyldecanol may possess the following formula: CH 3 (CH 2 )6CH2 ⁇ ⁇ -- ⁇ Q H
- Cosmetic compositions may include vitamin B compounds.
- vitamin B compounds include Bl compounds, B2 compounds, B3 compounds such as niacinamide, B5 compounds, such as panthenol or "pro-B5", pantothenic acid, pantothenyl, B6 compounds, such as pyroxidine, pyridoxal, pyridoxamine, carnitine, thiamine, and riboflavin.
- the vitamin B compound may be a B3 compound having the formula: wherein R is - CONH2 (i.e., niacinamide), - COOH (i.e., nicotinic acid) or - CH20H (i.e., nicotinyl alcohol); derivatives thereof; and salts of any of the foregoing.
- the cosmetic compositions may have a concentration of a vitamin B compound, by weight of the cosmetic composition, of greater than 0.0005%, 1%, 2%, 3%, 4%, or 5% and/or less than 11%, 10%, 8%, or 6%.
- the cosmetic compositions may have a concentration of a vitamin B compound, by weight of the cosmetic composition, of greater than about 0.0005%, 1%, 2%, 3%, 4%, or 5% and/or less than about 11%, 10%, 8%, or 6%.
- niacinamide may be associated with a variety of cosmetic skin care benefits. These may include: i) normalization of age associated depletions of nicotinamide coenzymes in skin, ii) up-regulation of epidermal ceramide synthesis with concurrent epidermal barrier benefits, iii) protection against damage produced by UV irradiation, iv) inhibition of the transfer of melanosomes from melanocytes to keratinocytes (thereby providing a potential skin tone benefit), and reduction in sebaceous lipogenesis.
- the cosmetic compositions may also comprise one or more humectants.
- humectants include sorbitol, honey, propylene glycol, and glycerin.
- Glycerin for example, is a small, polar molecule that is typically a liquid at room temperature and miscible with water. Endogenous glycerin is believed to be an important component of skin hydration and topical application of cosmetic products containing glycerin can be associated with improvements in barrier function, induction of biomarkers associated with keratinocyte proliferation and wound healing, reduction in melanin intensity, increases in epidermal thickness, and improvements in general skin appearance.
- the cosmetic compositions may have a concentration, by weight of the cosmetic composition, of greater than about 4%, 5%, 6%, 7%, 8%, 10%, 12%, 15%, 20% and/or less than about 30%, 25%, or 20% of one or more humectants.
- the cosmetic compositions may also comprise hydroxycinnamic acid, inositol, licorice extract, glycyrrhetinic acid, glab ridin, vitamin E succinate, salicylic acid, Laminaria Saccharina extract, Ficus Bengalensis extract, N-acetyl glucosamine, and combinations thereof.
- the cosmetic compositions described herein may also comprise one or more other ingredients.
- other ingredients commonly used in cosmetic compositions e.g., skin care actives
- methods of identifying skin care actives and/or methods of formulating cosmetic compositions are described in U.S. Publications Nos.
- the cosmetic composition may comprise from about 1% to about 95% by weight of water.
- the cosmetic composition may comprise from about 1% to about 95% by weight of one or more oils.
- the cosmetic composition may comprise from about 0.1%, 0.5%, 1%, 2%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, or 90% to about 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5%, or 3% of the one or more oils. Oils may be used to solubilize, disperse, or carry materials that are not suitable for water or water soluble solvents.
- Suitable oils include silicones, hydrocarbons, esters, amides, ethers, and mixtures thereof. Oils may be fluid at room temperature.
- the oils may be volatile or nonvolatile. "Non- volatile” means a material that exhibits a vapor pressure of no more than about 0.2 mm of mercury at 25°C at one atmosphere and/or a material that has a boiling point at one atmosphere of at least about 300°C. "Volatile” means that the material exhibits a vapor pressure of at least about 0.2 mm. of mercury at 20°C. Volatile oils may be used to provide a lighter feel when a heavy, greasy film is undesirable.
- oils are carriers typically associated with the oil phase.
- the cosmetic composition may be in the form of a water-in-oil emulsion, an oil-in-water emulsion, or a water- in- silicone emulsion.
- Suitable oils include volatile oils.
- the volatile oils may have a viscosity ranging from about 0.5 to 5 centistokes at 25 °C. Volatile oils may be used to promote more rapid drying of the cosmetic composition after it is applied to skin. Non-volatile oils are also suitable for use in the cosmetic composition. Non-volatile oils are often used for their emolliency and protective properties.
- Suitable silicone oils include polysiloxanes.
- Polylsiloxanes may have a viscosity of from about 0.5 to about 1,000,000 centistokes at 25°C.
- Such polysiloxanes can be represented by the general chemical formula:
- R 3 SiO[R 2 SiO] x SiR 3 wherein R is independently selected from hydrogen or C 1-3 o straight or branched chain, saturated or unsaturated alkyl, phenyl or aryl, trialkylsiloxy; and x is an integer from 0 to about 10,000, chosen to achieve the desired molecular weight.
- R include hydrogen, methyl, and ethyl.
- Commercially available polysiloxanes include the polydimethylsiloxanes, which are also known as dimethicones, examples of which include the DM-Fluid series from Shin-Etsu, the Vicasil ® series sold by Momentive Performance Materials Inc., and the Dow Corning ® 200 series sold by Dow Corning Corporation.
- suitable polydimethylsiloxanes include Dow Corning ® 200 fluids (also sold as Xiameter ® PMX-200 Silicone Fluids) having viscosities of 0.65, 1.5, 50, 100, 350, 10,000, 12,500 100,000, and 300,000 centistokes.
- Suitable dimethicones include those represented by the chemical formula:
- R3SiO[R 2 SiO] x [RR'SiO] y SiR3 wherein R and R are each independently hydrogen or C 1-3 o straight or branched chain, saturated or unsaturated alkyl, aryl, or trialkylsiloxy; and x and y are each integers of 1 to 1,000,000 selected to achieve the desired molecular weight.
- Non-limiting examples of dimethicones include phenyl dimethicone (BotansilTM PD- 151 from Botanigenics, Inc.), diphenyl dimethicone (KF-53 and KF-54 from Shin-Etsu), phenyl trimethicone (556 Cosmetic Grade Fluid from Dow Corning), or trimethylsiloxyphenyl dimethicone (PDM-20, PDM-200, or PDM-1000 from Wacker-Belsil).
- Other non-limiting examples include alkyl dimethicones wherein at least R' is a fatty alkyl (e.g. , C 12-22 ).
- a suitable alkyl dimethicone is cetyl dimethicone, wherein R' is a straight C16 chain and R is methyl. Cetyl dimethicone is available as 2502 Cosmetic Fluid from Dow Corning or as Abil Wax 9801 or 9814 from Evonik Goldschmidt GmbH.
- Cyclic silicones are one type of silicone oil that may be used in the cosmetic composition. Such silicones have the general formula:
- a mixture of cyclomethicones is used where n is 4, 5, and/or 6.
- Suitable hydrocarbon oils include straight, branched, or cyclic alkanes and alkenes.
- the chain length may be selected based on desired functional characteristics such as volatility.
- Suitable volatile hydrocarbons may have between 5-20 carbon atoms or, alternately, between 8- 16 carbon atoms.
- esters typically may contain at least 10 carbon atoms. These esters include esters with hydrocarbyl chains derived from fatty acids or alcohols (e.g., mono-esters, polyhydric alcohol esters, and di- and tri-carboxylic acid esters).
- the hydrocarbyl radicals of the esters hereof may include or have covalently bonded thereto other compatible functionalities, such as amides and alkoxy moieties (e.g., ethoxy or ether linkages, etc.).
- esters include, but are not limited to, isopropyl isostearate, hexyl laurate, isohexyl laurate, isohexyl palmitate, isopropyl palmitate, decyl oleate, isodecyl oleate, hexadecyl stearate, decyl stearate, isopropyl isostearate, dihexyldecyl adipate, lauryl lactate, myristyl lactate, cetyl lactate, oleyl stearate, oleyl oleate, oleyl myristate, lauryl acetate, cetyl propionate, C12-15 alkyl benzoate, diisopropyl adipate, dibutyl adipate, and oleyl adipate.
- esters suitable for use in the cosmetic composition include those known as polyhydric alcohol esters and glycerides.
- suitable oils include amides.
- Amides include compounds having an amide functional group while being liquid at 25°C and insoluble in water.
- Suitable amides include N- acetyl-N-butylaminopropionate, isopropyl N-lauroylsarcosinate, and ⁇ , ⁇ ,-diethyltoluamide.
- Other suitable amides are disclosed in U.S. Patent No. 6,872,401.
- Suitable oils include ethers.
- Suitable ethers include saturated and unsaturated fatty ethers of a polyhydric alcohol, and alkoxylated derivatives thereof.
- Exemplary ethers include C 4 _2o alkyl ethers of polypropylene glycols, and di-Cg_3o alkyl ethers. Suitable examples of these materials include PPG- 14 butyl ether, PPG- 15 stearyl ether, dioctyl ether, dodecyl octyl ether, and mixtures thereof.
- the cosmetic compositions may include an emulsifier.
- An emulsifier is particularly suitable when the cosmetic composition is in the form of an emulsion or if immiscible materials are being combined.
- the cosmetic composition may comprise from about 0.05%, 0.1%, 0.2%, 0.3%, 0.5%, or 1% to about 20%, 10%, 5%, 3%, 2%, or 1% emulsifier.
- Emulsifiers may be nonionic, anionic, zwitterionic, or cationic.
- Non-limiting examples of emulsifiers are disclosed in U.S. Patent 3,755,560, U.S. Patent 4,421,769, and McCutcheon's, Emulsifiers and Detergents, 2010 Annual Ed., published by M. C. Publishing Co.
- Other suitable emulsifiers are further described in the Personal Care Product Council's International Cosmetic Ingredient Dictionary and Handbook, Thirteenth Edition, 2006, under the functional category of "Surfactants - Emulsifying Agent
- Suitable emulsifiers include, but are not limited to, the following classes of ethers and esters: ethers of polyglycols and of fatty alcohols, esters of polyglycols and of fatty acids, ethers of polyglycols and of fatty alcohols which are glycosylated, esters of polyglycols and of fatty acids which are glycosylated, ethers of C 12 -3o alcohols and of glycerol or of polyglycerol, esters of C 12 -3o fatty acids and of glycerol or of polyglycerol, ethers of oxyalkylene-modified C 12 -3o alcohols and of glycerol or polyglycerol, ethers of C 12 -3o fatty alcohols comprising and of sucrose or of glucose, esters of sucrose and of C 12 -3o fatty acids, esters of pentaerythritol and of C 12 -3o fatty acids, esters of sorbi
- Linear or branched type silicone emulsifiers may also be used.
- examples of some useful polyether modified silicones include KF-6011, KF-6012, KF-6013, KF-6015, KF-6015, KF- 6017, KF-6043, KF-6028, and KF-6038 from Shin Etsu.
- examples of some useful silicone emulsifiers include the polyglycerolated linear or branched siloxane emulsifiers including KF- 6100, KF-6104, and KF-6105 from Shin Etsu.
- Emulsifiers also include emulsifying silicone elastomers. Suitable emulsifying silicone elastomers may include at least one polyalkyl ether or polyglycerolated unit. Polyoxyalylenated emulsifying silicone elastomers that may be used include those sold by Shin-Etsu Silicones under the names KSG-21, KSG-20, KSG-30, KSG-31, KSG-32, KSG-33; KSG-210 (dimethicone/PEG-10/15 crosspolymer dispersed in dimethicone); KSG-310 (PEG- 15 lauryl dimethicone crosspolymer); KSG-320 (PEG- 15 lauryl dimethicone crosspolymer dispersed in isododecane); KSG-330 (PEG- 15 lauryl dimethicone crosspolymer dispersed in triethylhexanoin), KSG-340 (PEG- 10 lauryl dimethicone
- silicone emulsifying elastomers are supplied by Dow CorningTM, including PEG-12 dimethicone crosspolymers (DC 9010 and 9011).
- PEG-12 dimethicone crosspolymers DC 9010 and 9011
- suitable silicone emulsifiers are sold by Dow Corning and include DC9010 and DC9011.
- Polyglycerolated emulsifying silicone elastomers are disclosed in PCT/WO 2004/024798.
- Such elastomers include Shin-Etsu's KSG series, such as KSG-710 (dimethicone/polyglycerin-3 crosspolymer dispersed in dimethicone); or lauryl dimethicone/polyglycerin-3 crosspolymer dispersed in a variety of solvent such as isododecane, dimethicone, triethylhexanoin, available as KSG-810, KSG-820, KSG-830, or KSG-840 from Shin-Etsu.
- Structuring agents may be used to increase viscosity, thicken, solidify, or provide solid or crystalline structure to the cosmetic composition. Structuring agents are typically grouped based on solubility, dispersibility, and phase compatibility. Examples of aqueous or water structuring agents include, but are not limited to, polymeric agents, natural or synthetic gums, polysaccharides, and the like.
- the cosmetic compositions may comprise from about 0.0001%, 0.001%, 0.01%, 0.05%, 0.1%, 0.5%, 1%, 2%, 3%, 5% to about 25%, 20%, 10%, 7%, 5%, 4%, or 2%, by weight of the cosmetic composition, of one or more structuring agents.
- Polysaccharides and gums may be examples of some suitable aqueous phase thickening agents.
- suitable classes of polymeric structuring agents include, but are not limited to, carboxylic acid polymers, polyacrylamide polymers, sulfonated polymers, high molecular weight polyalkylglycols or polyglycerins, copolymers thereof, hydrophobically modified derivatives thereof, and mixtures thereof.
- oil structuring agents examples include silicone and organic based materials. Suitable ranges of oil structuring agents are from about 0.01%, 0.05%, 0.1% 0.5%, 1%, 2.5%, 5%, or 10% to about 30%, 25%, 20%, 15%, 10%, or 5%.
- suitable oil phase structuring agents include those that are silicone based, such as silicone elastomers, silicone gums, silicone waxes, and linear silicones having a degree of polymerization allowing the silicone to increase the viscosity of the oil phase.
- silicone structuring agents include, but are not limited to, silicone elastomers, silicone gums, and silicone waxes,
- Suitable silicone elastomers may be in the powder form, or dispersed or solubilized in solvents such as volatile or non-volatile silicones, or silicone compatible vehicles such as paraffinic hydrocarbons or esters.
- silicone elastomer powders include vinyl dimethicone/methicone silsesquioxane crosspolymers like KSP-100, KSP-101, KSP-102, KSP- 103, KSP-104, KSP-105, available from Shin-Etsu, hybrid silicone powders that contain a fluoroalkyl group like KSP-200, available from Shin-Etsu, which is a fluoro- silicone elastomer, and hybrid silicone powders that contain a phenyl group such as KSP-300, available from Shin- Etsu, which is a phenyl substituted silicone elastomer; and DC 9506 available from Dow Corning.
- silicone elastomer dispersions include dimethicone/vinyl dimethicone crosspolymers supplied by a variety of suppliers including Dow Corning Corporation under the tradenames DC9040 or DC9041, Momentive under the tradename SFE 839, or Shin-Etsu Silicones under the tradenames KSG-15, 16, 18.
- KSG-15 has the INCI name cyclopentasiloxane (and) dimethicone/vinyl dimethicone crosspolymer.
- KSG- 18 has the INCI name diphenylsiloxy phenyl trimethicone (and) dimethicone/phenyl vinyl dimethicone crossoplymer.
- Silicone elastomers may also be purchased from Grant Industries under the Gransil trademark.
- Other suitable silicone elastomers have long chain alkyl substitutions such as lauryl dimethicone/vinyl dimethicone crosspolymers supplied by Shin Etsu under the tradenames KSG-41, KSG-42, KSG- 43, and KSG-44, wherein the elastomer is dispersed in solvents including mineral oil, isodocane, triethylhexanoin, or squalene, respectively.
- Suitable silicone elastomers may have polyglycerine substitutions such as lauryl dimethicone/polyglycerin-3 crosspolymers supplied by Shin Etsu under the tradenames KSG-810, KSG-820, KSG-830, and KSG-840, wherein the elastomer is dispersed in solvents including mineral oil, isodocane, triethylhexanoin, or squalene, respectively.
- polyglycerine substitutions such as lauryl dimethicone/polyglycerin-3 crosspolymers supplied by Shin Etsu under the tradenames KSG-810, KSG-820, KSG-830, and KSG-840, wherein the elastomer is dispersed in solvents including mineral oil, isodocane, triethylhexanoin, or squalene, respectively.
- suitable silicone elastomers may have polyglycol substitutions such as PEG- 15/lauryl dimethiconecrosspolymers supplied by Shin Etsu under the tradenames KSG-310, KSG-320, KSG-330, and KSG-340, wherein the elastomer is dispersed in solvents including mineral oil, isodocane, triethylhexanoin, or squalene, respectively.
- Other suitable silicone elastomers having polyglycol substitutions include Shin Etsu's KSG-210, a dimethicone/PEG- 10/15 crosspolymer in dimethicone.
- Silicone gums may be used as a structuring agent.
- the silicone gum may have a viscosity ranging from about 500,000 to 100 million est at 25°C, from about 600,000 to 20 million, from about 600,000 to 12 million est.
- Some suitable silicone gums include those sold by Wacker- Belsil under the trade names CM3092, Wacker-Belsil 1000, or Wacker-Belsil DM 3096.
- a particularly suitable silicone gum is dimethiconol, available from Dow Corning Corporation under the trade name 1-1254 Fluid, 2-9023 Fluid, and 2-9026 Fluid. Dimethiconol is often sold as a mixture with a volatile or nonvolatile silicone such as Dow Corning 1401 Fluid, 1403 Fluid, and 1501 Fluid.
- Silicone waxes may be referred to as alkyl silicone waxes and may be semi-solids or solids at room temperature.
- alkyl silicone wax means a polydimethylsiloxane having a substituted long chain alkyl (such as C16 to 30) that confers a semi-solid or solid property to the siloxane.
- examples of such silicone waxes include stearyl dimethicone, which may be purchased from Evonik Goldschmidt GmbH under the tradename Abil Wax 9800 or from Dow Corning under the tradename 2503.
- Another example is bis-stearyl dimethicone (which may be purchased from Gransil Industries under the tradename Gransil A- 18), behenyl dimethicone, or behenoxy dimethicone.
- Suitable structuring agents include polyamides and polysilicone-polyamide copolymers.
- Suitable polysilicone-polyamide copolymers are disclosed in U.S. Patent Application Publication No. 2004/0170586.
- Other structuring agents may be one or more natural or synthetic waxes such as animal, vegetable, or mineral waxes.
- Suitable silicone waxes are disclosed in U.S. Patent Nos. 5,413,781 and 5,725,845, and further include alkylmethyl polysiloxanes, CIO - C60 alkyl dimethicones, and mixtures thereof.
- structuring agents include natural or synthetic montmorillonite minerals, silicas, silicates, silica silylate, and alkali metal or alkaline earth metal derivatives thereof.
- the cosmetic compositions may optionally contain one or more UV actives.
- UV active includes both sunscreen agents and physical sunblocks. Suitable UV actives may be organic or inorganic. Examples of some suitable UV actives are listed in the functional category of "Sunscreen Agents" in the Personal Care Product Council's International Cosmetic Ingredient Dictionary and Handbook, Thirteenth Edition, 2010. Suitable UV actives include those defined or proposed by regulatory agencies in the US (e.g., 21 CFR part 352, 68 Federal Register 41386, 70 Federal Register 72449, or 71 Federal Register 42405), Europe (Regulation No 1223/2009 of the EU Parliament; Annex VI), Japan, China, Australia, New Zealand, or Canada.
- the cosmetic composition may comprise from about 0.01% to about 20%, by weight of the cosmetic composition, of a UV active.
- the cosmetic composition may also comprise a sufficient amount of one or more UV actives to yield a Sun Protection Factor of at least about 15, 30, 45, or 50.
- SPF testing is conventional and well understood in the art. A suitable SPF test is prescribed in 21 C.F.R. 352, Subpart D.
- UV actives include dibenzoylmethane derivatives including 2- methyldibenzoylmethane, 4-methyldibenzoylmethane, 4-isopropyldibenzoylmethane, 4-tert- butyldibenzoylmethane, 2,4- dimethyldibenzoylmethane, 2,5- dimethyldibenzoylmethane, 4,4'- diisopropyldibenzoylmethane, 4,4'-dimethoxy dibenzoylmethane, 4-tert-butyl-4'-methoxy dibenzoylmethane (i.e., butyl methoxydibenzoylmethane or avobenzone) (commercially available as PARSOL ® 1789 from DSM), 2-methyl-5-isopropyl-4'-methoxy dibenzoylmethane, 2-methyl- 5-tert-butyl-4'-methoxydibenzoylmethane
- UV actives include 2- ethylhexyl-p-methoxycinnamate (commercially available as PARSOL ® MCX from DSM), 2- hydroxy-4-methoxybenzophenone, benzonphenone-3 (i.e.
- octyldimethyl-p- aminobenzoic acid digalloyltrioleate, 2,2-dihydroxy-4-methoxybenzophenone, ethyl-4- (bis(hydroxy-propyl))aminobenzoate, 2-ethylhexyl-2-cyano-3,3-diphenylacrylate, 2-ethylhexyl- salicylate, glyceryl-p-aminobenzoate, 3,3,5-tri-methylcyclohexylsalicylate, methylanthranilate, p- dimethyl-aminobenzoic acid or aminobenzoate, 2-ethylhexyl-p-dimethyl-amino-benzoate, 2- phenylbenzimidazole-5-sulfonic acid, 2-(p-dimethylaminophenyl)-5-sulfonicbenzoxazoic acid, octocrylene, zinc oxide, titanium dioxide,
- UV actives are 2-ethylhexyl-p-methoxycinnamate, 4-tert-butyl-4'- methoxy dibenzoylmethane, 2-hydroxy-4-methoxybenzo-phenone, 2-phenylbenzimidazole-5- sulfonic acid, octocrylene, zinc oxide, titanium dioxide, and mixtures thereof.
- UV actives include 4-methylbenzylidene camphor (commercially available as PARSOL ® 5000 from DSM or Eusolex 6300 from Merck), methylene bis- benzotriazolyl tetramethylbutylphenol (i.e., bisoctrizole, commercially available as Tinosorb ® M from BASF), bis-ethylhexyloxyphenol methoxyphenol triazine (i.e., bemotrizinol,commercially available as Tinosorb ® S from BASF), disodium phenyl dibenzimidazole tetrasulfonate (i.e., Bisdisulizole disodium, commercially available as Neo Heliopan ® AP from Symrise), Ethylhexyl triazone (commercially available as Uvinul ® T 150 from BASF), Drometrizole trisiloxane (marketed as Mexoryl XL by L'Oreal), Sodium Dihydroxy Dimethoxy Disulf
- the cosmetic compositions may be generally prepared by conventional methods such as those known in the art of making cosmetic compositions. Such methods typically involve mixing of ingredients in one or more steps to a relatively uniform state, with or without heating, cooling, application of vacuum, and the like. Typically, emulsions are prepared by first mixing the aqueous phase materials separately from the fatty phase materials and then combining the two phases as appropriate to yield the desired continuous phase.
- the cosmetic compositions are preferably prepared such as to optimize stability (physical stability, chemical stability, photo stability, etc.) and/or delivery of active materials.
- the cosmetic composition may be provided in a package sized to store a sufficient amount of the cosmetic composition for a treatment period. The size, shape, and design of the package may vary widely.
- a B16-F1 mouse melanoma cell line may be employed as an assay to measure melanin synthesis.
- the B16-F1 cells may be obtained from American Tissue Culture Collection, Virginia, USA.
- the cell culture medium that may be used in the assay may comprise 500 mL of Dulbecco' s Modified Eagle's Medium (DMEM), 50 mL Fetal Bovine Serum (FBS), and 5 mL of penicillin-streptomycin liquid.
- DMEM Dulbecco' s Modified Eagle's Medium
- FBS Fetal Bovine Serum
- penicillin-streptomycin liquid 500 mL of penicillin-streptomycin liquid.
- B16-F1 cells that are cultured in this medium and grown to greater than 90% confluency synthesize melanin. While not intending to be bound by any theory, it is hypothesized that melanin synthesis is stimulated by the culture medium and/or stress induced by growth to a high confluency.
- the DMEM and FBS can be obtained from American Tissue Culture Collection and the penicillin- streptomycin liquid can be obtained from Invitrogen, Inc., California, USA.
- Equipment used in the assay include a C0 2 incubator, such as a Forma Series Model 3110 by Therma Scientific, Massachusets, USA; a hemocytometer, such as a Bright Line model by Hauser Scientific, Pennsylvania, USA; and a UV- Visible Spectrum Plate Reader, such as a SpectraMax250 from Molecular Devices, California, USA.
- the assay steps may include:
- Day 0 - Cell Growth Warm the cell culture medium to 37°C and place 29 mL into a T- 150 flask. Add approximately 1 x 10 6 of B16-F1 passage 1 mouse cells to the T-150 flask and incubate for 3 days at 37°C, 5% C0 2 , 90% relative humidity, until -80% confluency;
- Day 3 Initiate a 96 Well Plate: At day 3, trypsinize the cells from the T-150 flask and determine the concentration of cells using a hemocytometer. Initiate a 96 well plate with 2,500 cells per well in 100 microliters of cell culture medium. Incubate the plate at 37 °C, 5% C0 2 , 90% relative humidity for about 2 days until at least 20% to 40% confluency;
- Controls comprise wells having the cell culture medium, B16-F1 cells, and the solvent (control #1); wells comprising the cell culture medium and the solvent (control #2); and optionally wells comprising the cell culture medium, solvent and [test compound] when necessary to control for the [test compound] background color (control #3);
- OD410 is the Optical Density at 410 nm as measured by the UV-Vis Spectrum
- Control #3 the formula for percentage melanin synthesis inhibition is: 100 - [OD410 Test Compound - OD410 Control #3] X 100 (OD410 Control #1 - OD410 Control #2)
- the cosmetic compositions disclosed herein may be applied to one or more skin surfaces and/or one or more mammalian keratinous tissue surfaces as part of a user's daily routine or regimen. Additionally or alternatively, the cosmetic compositions herein may be used on an "as needed" basis. In some examples, an effective amount of the cosmetic composition may be applied to the target portion of the keratinous tissue or skin.
- the method may include a step of identifying a target portion of keratinous tissue or skin comprising one or more of the following for treatment with the cosmetic composition: age spots, pigment spots, uneven skin tone, and/or in need of melanin reduction.
- the method may also include a step of identifying a skin surface for treatment with the cosmetic composition for improving skin condition.
- the skin surface may be identified by the user or a third party such as a dermatologist, cosmetician, or other individual or even by a combination of different individuals. Identification may be done, for example, by visual inspection of the skin surface in need of treatment based on size and/or color.
- Identification may also be done by either custom- made or commercially available imaging devices such as SIAscope V (available from Astron Clinica, Ltd., UK) or the VISIA ® Complexion Analysis system (available from Canfield Scientific, Inc., Fairfield, NJ). Both devices are capable of collecting images of the skin and identifying age spots. Identification may also be done, for example, by color meter or spectrophotometer, which are both capable of collecting skin color information of basal area and/or age spots.
- SIAscope V available from Astron Clinica, Ltd., UK
- VISIA ® Complexion Analysis system available from Canfield Scientific, Inc., Fairfield, NJ. Both devices are capable of collecting images of the skin and identifying age spots.
- Identification may also be done, for example, by color meter or spectrophotometer, which are both capable of collecting skin color information of basal area and/or age spots.
- Skin surfaces may include those not typically covered by clothing such as facial skin surfaces, hand and arm skin surfaces, foot and leg skin surfaces, and neck and chest skin surfaces (e.g., decolletage).
- areas identified for treatment may include areas such as the forehead, perioral, chin, periorbital, nose, and/or cheek skin surfaces.
- the cosmetic composition may be applied to any facial skin care surface and/or any other skin surface identified as in need of treatment by the cosmetic composition.
- one or more of these skin surfaces may be identified as needing treatment and one or more of these skins surfaces may be treated with the cosmetic composition.
- the method may comprise a step of applying the composition to the skin surface, which may or may not have been previously identified.
- the cosmetic composition may be applied as needed and/or at least once a day, twice a day, or on a more frequent daily basis, during a treatment period.
- Non-limiting examples of the treatment periods may be between about 1 week and about 12 weeks, between about 4 weeks and about 12 weeks, and/or between about 4 weeks and about 8 weeks.
- the treatment period may extend over multiple months (i.e. , 3-12 months) or multiple years.
- the cosmetic composition may be applied least once a day during a treatment period of at least about 4 weeks or at least about 8 weeks.
- the cosmetic composition may be applied twice a day during a treatment period of at least about 4 weeks or 8 weeks.
- the cosmetic composition can also be applied to at least one skin surface area at least once per day, twice per day, or three times per day for a period of 7, 14, 21, or 28 days or more.
- the first and second applications may be separated by at least 1 to about 12 hours.
- the cosmetic composition may be also applied in the morning and/or in the evening before bed.
- the treatment period should be a sufficient time to provide an improvement in the skin surface but need not be so.
- Non-limiting examples of improvements include a detectable reductions in the size of the age spot(s), lightening of the age spot(s) (e.g. , lighter in color), a decrease in melanin levels, and an improvement in melanin evenness.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020177028236A KR101952529B1 (en) | 2013-03-15 | 2014-03-06 | Cosmetic compositions and methods for inhibiting melanin synthesis |
EP14712505.8A EP2900207A1 (en) | 2013-03-15 | 2014-03-06 | Cosmetic compositions and methods for inhibiting melanin synthesis |
CN201480002944.0A CN104780897A (en) | 2013-03-15 | 2014-03-06 | Cosmetic compositions and methods for inhibiting melanin synthesis |
JP2015542054A JP2015537006A (en) | 2013-03-15 | 2014-03-06 | Cosmetic composition and method for inhibiting melanin synthesis |
CA2890526A CA2890526A1 (en) | 2013-03-15 | 2014-03-06 | Cosmetic compositions and methods for inhibiting melanin synthesis |
IN3897DEN2015 IN2015DN03897A (en) | 2013-03-15 | 2014-03-06 | |
KR1020157012026A KR20150065875A (en) | 2013-03-15 | 2014-03-06 | Cosmetic compositions and methods for inhibiting melanin synthesis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361794122P | 2013-03-15 | 2013-03-15 | |
US61/794,122 | 2013-03-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014149867A1 true WO2014149867A1 (en) | 2014-09-25 |
Family
ID=50349951
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2014/021271 WO2014149867A1 (en) | 2013-03-15 | 2014-03-06 | Cosmetic compositions and methods for inhibiting melanin synthesis |
Country Status (8)
Country | Link |
---|---|
US (2) | US20140271506A1 (en) |
EP (1) | EP2900207A1 (en) |
JP (2) | JP2015537006A (en) |
KR (2) | KR20150065875A (en) |
CN (1) | CN104780897A (en) |
CA (1) | CA2890526A1 (en) |
IN (1) | IN2015DN03897A (en) |
WO (1) | WO2014149867A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016040757A1 (en) * | 2014-09-12 | 2016-03-17 | The Procter & Gamble Company | Cosmetic compositions and methods for inhibiting melanin synthesis |
US10159637B2 (en) | 2016-06-10 | 2018-12-25 | Clarity Cosmetics Inc. | Non-comedogenic and non-acnegenic hair and scalp care formulations and method for use |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112017010702A2 (en) * | 2014-11-24 | 2018-02-14 | Oreal | composition, use of a synthetic phyllosilicate, cosmetic use of a composition, cosmetic treatment process, cosmetic process |
CN107233223B (en) * | 2017-06-16 | 2019-01-25 | 湖南御家化妆品制造有限公司 | Control induction melanin target composition and its application |
CN112218616A (en) | 2018-03-23 | 2021-01-12 | 玫琳凯有限公司 | Topical compositions and methods |
CN115003274B (en) | 2020-01-24 | 2024-06-18 | 宝洁公司 | Skin care composition |
US10959933B1 (en) * | 2020-06-01 | 2021-03-30 | The Procter & Gamble Company | Low pH skin care composition and methods of using the same |
WO2022132688A1 (en) | 2020-12-14 | 2022-06-23 | The Procter & Gamble Company | Method of treating oxidative stress in skin and compositions therefor |
CN114931522B (en) * | 2022-06-15 | 2023-05-23 | 江南大学 | Emulsion containing undecylenoyl phenylalanine and preparation method thereof |
Citations (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3755560A (en) | 1971-06-30 | 1973-08-28 | Dow Chemical Co | Nongreasy cosmetic lotions |
US4421769A (en) | 1981-09-29 | 1983-12-20 | The Procter & Gamble Company | Skin conditioning composition |
US5413781A (en) | 1991-01-17 | 1995-05-09 | Dow Corning Corporation | Alkylmethylsiloxanes for skin care |
USD391162S (en) | 1996-10-04 | 1998-02-24 | The Procter & Gamble Company | Combined jar and cover |
US5725845A (en) | 1995-11-03 | 1998-03-10 | Revlon Consumer Products Corporation | Transfer resistant cosmetic stick compositions with semi-matte finish |
US5872112A (en) | 1991-11-25 | 1999-02-16 | Richardson-Vicks Inc. | Use of salicylic acid for regulating skin wrinkles and/or skin atrophy |
US5939082A (en) | 1995-11-06 | 1999-08-17 | The Procter & Gamble Company | Methods of regulating skin appearance with vitamin B3 compound |
US5972359A (en) | 1997-05-23 | 1999-10-26 | The Procter & Gamble Company | Skin care compositions and method of improving skin appearance |
US6174533B1 (en) | 1997-05-23 | 2001-01-16 | The Procter & Gamble Company | Skin care compositions and method of improving skin appearance |
US20020022040A1 (en) | 2000-07-10 | 2002-02-21 | The Proctor & Gamble Company | Methods of enhancing delivery of oil-soluble skin care actives |
US6492326B1 (en) | 1999-04-19 | 2002-12-10 | The Procter & Gamble Company | Skin care compositions containing combination of skin care actives |
US6524598B2 (en) | 2000-07-10 | 2003-02-25 | The Procter & Gamble Company | Cosmetic compositions |
US6696049B2 (en) | 2000-07-10 | 2004-02-24 | The Procter & Gamble Company | Cosmetic compositions |
WO2004024798A1 (en) | 2002-09-12 | 2004-03-25 | Shin-Etsu Chemical Co., Ltd. | Novel organopolysiloxane polymer, pasty composition, and cosmetic preparation containing the composition |
US20040170586A1 (en) | 2002-06-12 | 2004-09-02 | L'oreal | Cosmetic composition containing a polyorganosiloxane polymer |
US6872401B2 (en) | 2002-03-28 | 2005-03-29 | L'oreal | Cosmetic/dermatological compositions comprising a tetrahydrocurcuminoid and an amide oil |
USD516436S1 (en) | 2004-08-27 | 2006-03-07 | The Procter & Gamble Company | Container |
USD535191S1 (en) | 2004-04-27 | 2007-01-16 | The Procter & Gamble Company | Tube |
US20070040306A1 (en) | 2003-04-02 | 2007-02-22 | Sabrina Morel | Method for carrying out ventilation in a multi-walled container |
USD542660S1 (en) | 2004-06-18 | 2007-05-15 | The Procter & Gamble Company | Container |
USD547193S1 (en) | 2004-11-04 | 2007-07-24 | The Procter & Gamble Company | Product container |
USD547661S1 (en) | 2006-06-29 | 2007-07-31 | The Procter & Gamble Company | Cream jar |
US20070196344A1 (en) | 2006-01-20 | 2007-08-23 | The Procter & Gamble Company | Methods for identifying materials that can help regulate the condition of mammalian keratinous tissue |
US20070205226A1 (en) | 2004-12-24 | 2007-09-06 | The Procter And Gamble Company | Discharge Container |
USD558591S1 (en) | 2006-08-14 | 2008-01-01 | The Procter & Gamble Company | Bottle |
USD563221S1 (en) | 2006-10-23 | 2008-03-04 | The Procter & Gamble Company | Cosmetic container |
USD570707S1 (en) | 2006-06-29 | 2008-06-10 | The Procter & Gamble Company | Lotion pump package |
US20080181956A1 (en) | 2007-01-31 | 2008-07-31 | The Procter & Gamble Company | Oil-in-water personal care composition |
US20080206373A1 (en) | 2007-02-28 | 2008-08-28 | Cheri Lynn Millikin | Personal Care Composition Comprising Botanical Extract |
WO2008105632A1 (en) * | 2007-02-27 | 2008-09-04 | Biospectrum Inc. | Compositions for improving skin conditions comprising alpha-bisabolol as an active ingrdient |
US20090017080A1 (en) | 2007-03-15 | 2009-01-15 | Paul Robert Tanner | Personal care kit having skin care compositions with a readily perceptible difference |
US20100092408A1 (en) | 2008-10-14 | 2010-04-15 | Laurie Ellen Breyfogle | Resilient personal care composition comprising polyalkyl ether containing siloxane elastomers |
US20100189669A1 (en) | 2009-01-29 | 2010-07-29 | Tomohiro Hakozaki | Regulation of Mammalian Keratinous Tissue Using Skin and/or Hair Care Actives |
US20100239510A1 (en) | 2009-01-22 | 2010-09-23 | Robert Bao Kim Ha | Skin-care composition comprising dill extract |
US20110097286A1 (en) | 2009-01-29 | 2011-04-28 | Cheri Lynn Swanson | Compositions and methods for inhibiting par2 activation of keratinocytes |
US20110262025A1 (en) | 2010-02-05 | 2011-10-27 | Bradley Bryan Jarrold | Cosmetic Compositions and Methods for Maintaining and Improving Barrier Function of the Stratum Corneum and to Reduce the Visible Signs of Aging in Skin |
US20120128683A1 (en) | 2011-11-22 | 2012-05-24 | Shantha Totada R | Autism treatment |
WO2012068195A1 (en) * | 2010-11-18 | 2012-05-24 | The Procter & Gamble Company | Cosmetic compositions based on a n-acyl amino acid compound and hexyldecanol |
WO2012068357A2 (en) * | 2010-11-19 | 2012-05-24 | The Procter & Gamble Company | Cosmetic compositions and methods for inhibiting or reducing trypsin activity |
US20120156146A1 (en) | 2010-11-19 | 2012-06-21 | Tomohiro Hakozaki | Compositions and Methods for Improving the Appearance of Facial Texture |
US20120197016A1 (en) | 2010-10-25 | 2012-08-02 | The Procter & Gamble Company | Screening methods of modulating adrenergic receptor gene expressions implicated in melanogenesis |
US20130022557A1 (en) | 2011-07-22 | 2013-01-24 | Cheri Lynn Swanson | Methods For Improving the Appearance of Hyperpigmented Spot(s) Using an Extract of Laminaria Saccharina |
-
2014
- 2014-03-06 EP EP14712505.8A patent/EP2900207A1/en not_active Withdrawn
- 2014-03-06 IN IN3897DEN2015 patent/IN2015DN03897A/en unknown
- 2014-03-06 JP JP2015542054A patent/JP2015537006A/en active Pending
- 2014-03-06 CN CN201480002944.0A patent/CN104780897A/en active Pending
- 2014-03-06 WO PCT/US2014/021271 patent/WO2014149867A1/en active Application Filing
- 2014-03-06 KR KR1020157012026A patent/KR20150065875A/en not_active Application Discontinuation
- 2014-03-06 KR KR1020177028236A patent/KR101952529B1/en active IP Right Grant
- 2014-03-06 CA CA2890526A patent/CA2890526A1/en not_active Abandoned
- 2014-03-13 US US14/209,532 patent/US20140271506A1/en not_active Abandoned
-
2015
- 2015-08-19 US US14/830,341 patent/US20150352022A1/en not_active Abandoned
-
2017
- 2017-06-30 JP JP2017128798A patent/JP2017190334A/en active Pending
Patent Citations (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3755560A (en) | 1971-06-30 | 1973-08-28 | Dow Chemical Co | Nongreasy cosmetic lotions |
US4421769A (en) | 1981-09-29 | 1983-12-20 | The Procter & Gamble Company | Skin conditioning composition |
US5413781A (en) | 1991-01-17 | 1995-05-09 | Dow Corning Corporation | Alkylmethylsiloxanes for skin care |
US5872112A (en) | 1991-11-25 | 1999-02-16 | Richardson-Vicks Inc. | Use of salicylic acid for regulating skin wrinkles and/or skin atrophy |
US5725845A (en) | 1995-11-03 | 1998-03-10 | Revlon Consumer Products Corporation | Transfer resistant cosmetic stick compositions with semi-matte finish |
US5939082A (en) | 1995-11-06 | 1999-08-17 | The Procter & Gamble Company | Methods of regulating skin appearance with vitamin B3 compound |
USD391162S (en) | 1996-10-04 | 1998-02-24 | The Procter & Gamble Company | Combined jar and cover |
US5972359A (en) | 1997-05-23 | 1999-10-26 | The Procter & Gamble Company | Skin care compositions and method of improving skin appearance |
US6174533B1 (en) | 1997-05-23 | 2001-01-16 | The Procter & Gamble Company | Skin care compositions and method of improving skin appearance |
US6492326B1 (en) | 1999-04-19 | 2002-12-10 | The Procter & Gamble Company | Skin care compositions containing combination of skin care actives |
US20030049212A1 (en) | 2000-07-10 | 2003-03-13 | The Procter & Gamble Company | Skin care compositions containing silicone elastomers |
US20020022040A1 (en) | 2000-07-10 | 2002-02-21 | The Proctor & Gamble Company | Methods of enhancing delivery of oil-soluble skin care actives |
US6696049B2 (en) | 2000-07-10 | 2004-02-24 | The Procter & Gamble Company | Cosmetic compositions |
US6524598B2 (en) | 2000-07-10 | 2003-02-25 | The Procter & Gamble Company | Cosmetic compositions |
US6872401B2 (en) | 2002-03-28 | 2005-03-29 | L'oreal | Cosmetic/dermatological compositions comprising a tetrahydrocurcuminoid and an amide oil |
US20040170586A1 (en) | 2002-06-12 | 2004-09-02 | L'oreal | Cosmetic composition containing a polyorganosiloxane polymer |
WO2004024798A1 (en) | 2002-09-12 | 2004-03-25 | Shin-Etsu Chemical Co., Ltd. | Novel organopolysiloxane polymer, pasty composition, and cosmetic preparation containing the composition |
US20070040306A1 (en) | 2003-04-02 | 2007-02-22 | Sabrina Morel | Method for carrying out ventilation in a multi-walled container |
USD535191S1 (en) | 2004-04-27 | 2007-01-16 | The Procter & Gamble Company | Tube |
USD542660S1 (en) | 2004-06-18 | 2007-05-15 | The Procter & Gamble Company | Container |
USD516436S1 (en) | 2004-08-27 | 2006-03-07 | The Procter & Gamble Company | Container |
USD547193S1 (en) | 2004-11-04 | 2007-07-24 | The Procter & Gamble Company | Product container |
US20070205226A1 (en) | 2004-12-24 | 2007-09-06 | The Procter And Gamble Company | Discharge Container |
US20070196344A1 (en) | 2006-01-20 | 2007-08-23 | The Procter & Gamble Company | Methods for identifying materials that can help regulate the condition of mammalian keratinous tissue |
USD547661S1 (en) | 2006-06-29 | 2007-07-31 | The Procter & Gamble Company | Cream jar |
USD570707S1 (en) | 2006-06-29 | 2008-06-10 | The Procter & Gamble Company | Lotion pump package |
USD558591S1 (en) | 2006-08-14 | 2008-01-01 | The Procter & Gamble Company | Bottle |
USD563221S1 (en) | 2006-10-23 | 2008-03-04 | The Procter & Gamble Company | Cosmetic container |
US20080181956A1 (en) | 2007-01-31 | 2008-07-31 | The Procter & Gamble Company | Oil-in-water personal care composition |
WO2008105632A1 (en) * | 2007-02-27 | 2008-09-04 | Biospectrum Inc. | Compositions for improving skin conditions comprising alpha-bisabolol as an active ingrdient |
US20080206373A1 (en) | 2007-02-28 | 2008-08-28 | Cheri Lynn Millikin | Personal Care Composition Comprising Botanical Extract |
US20090017080A1 (en) | 2007-03-15 | 2009-01-15 | Paul Robert Tanner | Personal care kit having skin care compositions with a readily perceptible difference |
US20100092408A1 (en) | 2008-10-14 | 2010-04-15 | Laurie Ellen Breyfogle | Resilient personal care composition comprising polyalkyl ether containing siloxane elastomers |
US20100239510A1 (en) | 2009-01-22 | 2010-09-23 | Robert Bao Kim Ha | Skin-care composition comprising dill extract |
US20100189669A1 (en) | 2009-01-29 | 2010-07-29 | Tomohiro Hakozaki | Regulation of Mammalian Keratinous Tissue Using Skin and/or Hair Care Actives |
US20110097286A1 (en) | 2009-01-29 | 2011-04-28 | Cheri Lynn Swanson | Compositions and methods for inhibiting par2 activation of keratinocytes |
US20110262025A1 (en) | 2010-02-05 | 2011-10-27 | Bradley Bryan Jarrold | Cosmetic Compositions and Methods for Maintaining and Improving Barrier Function of the Stratum Corneum and to Reduce the Visible Signs of Aging in Skin |
US20120197016A1 (en) | 2010-10-25 | 2012-08-02 | The Procter & Gamble Company | Screening methods of modulating adrenergic receptor gene expressions implicated in melanogenesis |
WO2012068195A1 (en) * | 2010-11-18 | 2012-05-24 | The Procter & Gamble Company | Cosmetic compositions based on a n-acyl amino acid compound and hexyldecanol |
WO2012068357A2 (en) * | 2010-11-19 | 2012-05-24 | The Procter & Gamble Company | Cosmetic compositions and methods for inhibiting or reducing trypsin activity |
US20120148515A1 (en) | 2010-11-19 | 2012-06-14 | Tomohiro Hakozaki | Cosmetic Compositions and Methods for Inhibiting or Reducing Trypsin Activity |
US20120156146A1 (en) | 2010-11-19 | 2012-06-21 | Tomohiro Hakozaki | Compositions and Methods for Improving the Appearance of Facial Texture |
US20130022557A1 (en) | 2011-07-22 | 2013-01-24 | Cheri Lynn Swanson | Methods For Improving the Appearance of Hyperpigmented Spot(s) Using an Extract of Laminaria Saccharina |
US20120128683A1 (en) | 2011-11-22 | 2012-05-24 | Shantha Totada R | Autism treatment |
Non-Patent Citations (3)
Title |
---|
"International Cosmetic Ingredient Dictionary and Handbook, Thirteenth Edition,", 2010, article "Personal Care Product Council's" |
"McCutcheon's, Emulsifiers and Detergents", 2010, M. C. PUBLISHING CO. |
DATABASE GNPD [online] MINTEL; May 2012 (2012-05-01), "Dark Spot Corrector", XP002727175, Database accession no. 1788727 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016040757A1 (en) * | 2014-09-12 | 2016-03-17 | The Procter & Gamble Company | Cosmetic compositions and methods for inhibiting melanin synthesis |
US10159637B2 (en) | 2016-06-10 | 2018-12-25 | Clarity Cosmetics Inc. | Non-comedogenic and non-acnegenic hair and scalp care formulations and method for use |
US10813872B2 (en) | 2016-06-10 | 2020-10-27 | Clarity Cosmetics Inc. | Hair and scalp formulations |
US11160746B2 (en) | 2016-06-10 | 2021-11-02 | Clarity Cosmetics Inc. | Non-comedogenic and non-acnegenic hair and scalp care formulations and method for use |
Also Published As
Publication number | Publication date |
---|---|
KR101952529B1 (en) | 2019-02-26 |
JP2017190334A (en) | 2017-10-19 |
EP2900207A1 (en) | 2015-08-05 |
IN2015DN03897A (en) | 2015-10-02 |
KR20150065875A (en) | 2015-06-15 |
KR20170117234A (en) | 2017-10-20 |
CN104780897A (en) | 2015-07-15 |
JP2015537006A (en) | 2015-12-24 |
US20140271506A1 (en) | 2014-09-18 |
CA2890526A1 (en) | 2014-09-25 |
US20150352022A1 (en) | 2015-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2890512C (en) | Cosmetic compositions and methods for inhibiting melanin synthesis | |
CA2958428C (en) | Cosmetic compositions and methods for inhibiting melanin synthesis | |
WO2014149867A1 (en) | Cosmetic compositions and methods for inhibiting melanin synthesis | |
US9511144B2 (en) | Cosmetic compositions and methods providing enhanced penetration of skin care actives | |
US9192552B2 (en) | Personal care compositions with improved solubility of a solid UV active | |
JP2014520818A (en) | Personal care compositions with improved dissolution properties of solid cosmetic ingredients | |
JP6523291B2 (en) | Cosmetic composition and method for providing high penetration of skin care active ingredients | |
WO2024003594A1 (en) | Personal care compositions comprising pancratium maritimum |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14712505 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014712505 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2890526 Country of ref document: CA Ref document number: 20157012026 Country of ref document: KR Kind code of ref document: A Ref document number: 2015542054 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |